Emtricitabine/rilpivirine/tenofovir
| Combination of | |
|---|---|
| Emtricitabine | Nucleoside analog reverse-transcriptase inhibitor |
| Rilpivirine | Non-nucleoside reverse transcriptase inhibitor |
| Tenofovir disoproxil | Nucleotide analog reverse-transcriptase inhibitor |
| Clinical data | |
| Trade names | Complera, Eviplera |
| AHFS/Drugs.com | Multum Consumer Information |
| MedlinePlus | a616021 |
| License data | |
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| KEGG | |
| (verify) | |
Emtricitabine/rilpivirine/tenofovir, sold under the brand name Complera among others, is a fixed-dose combination of antiretroviral drugs for the treatment of HIV/AIDS.[4] The drug was co-developed by Gilead Sciences and Johnson & Johnson's Tibotec division and was approved by the US Food and Drug Administration (FDA) in August 2011, and by the European Medicines Agency in November 2011,[3][5] for patients who have not previously been treated for HIV.[6] It is available as a once-a-day single tablet.
In the European Union it is marketed as Eviplera and in the US as Complera.[7]
- ^ "Complera- emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate tablet, film coated". DailyMed. 26 March 2021. Retrieved 20 June 2024.
- ^ "Complera Access - emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate tablet, film coated". DailyMed. 20 February 2024. Retrieved 20 June 2024.
- ^ a b "Eviplera EPAR". European Medicines Agency. 28 November 2011. Retrieved 20 June 2024.
- ^ "Approval of Complera: emtricitabine/rilpivirine/tenofovir DF fixed dose combination". U.S. Food and Drug Administration (FDA). 10 August 2011. Archived from the original on 18 August 2011.
- ^ "Eviplera; summary of the European public assessment report". European Medicines Agency. November 2011. Archived from the original on 24 May 2013. Retrieved 29 January 2012.
- ^ "FDA approves Gilead-J&J HIV pill Complera". Business Week. 10 August 2011. Archived from the original on 10 September 2011.
- ^ Complera/Eviplera (Rilpivirine + emtricitabine + tenofovir) Archived 9 August 2017 at the Wayback Machine, aidsinfonet.org